-REGENXBIO AAV Therapeutics pipeline to be
discussed by management and external experts
-Focus on programs for Wet AMD, Diabetic
Retinopathy, and Duchenne Muscular Dystrophy
ROCKVILLE, Md., June 27,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a virtual investor day on
July 11, 2023. During the event,
members of REGENXBIO's management team and external experts will
provide an update to the investment community on the Company's
pipeline, with a focus on programs with expected interim clinical
trial data to be presented in the second half of 2023.
The program will include presentations of the ABBV-RGX-314 eye
care program, including plans for interim data updates from the
Phase II AAVIATE® and ALTITUDE® trials. It
will also include an overview of RGX-202, an investigational
one-time gene therapy utilizing a novel microdystrophin construct
for the treatment of Duchenne Muscular Dystrophy (Duchenne),
including the expected plans for interim data updates from the
Phase I/II AFFINITY DUCHENNE™ trial.
In addition, management will highlight the features and
performance of the fully operational REGENXBIO Manufacturing
Innovation Center, which is designed to support commercial
readiness. This facility is producing GMP lots to support the
ABBV-RGX-314 and RGX-202 programs using the NAVXpress™ platform
process, which has demonstrated the ability to increase product
purity and yield.
A live question and answer session will follow the program.
The event will feature the following external experts:
- George Dickson, world-class researcher in Duchenne and
Professor of Molecular Cell Biology at Royal Holloway – University
of London.
- Dr. Peter Kaiser, MD FASRS,
Chair for Ophthalmology Research and a Professor of Ophthalmology
at the Cleveland Clinic Lerner College of Medicine.
- Dr. Veeral Sheth, MD, MBA, FACS, FASRS, board-certified
vitreoretinal surgeon and Partner at University Retina and Macula
Associates in Chicago.
The virtual event will take place on Tuesday, July 11, 2023 at 8:30 a.m. Eastern Time. The webcast and slides of
the presentation can be accessed in the Investors section of
REGENXBIO's website at www.regenxbio.com. An archived replay of the
webcast will be available in the Investors section of REGENXBIO's
website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Forward-Looking Statement
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "assume," "design,"
"intend," "expect," "could," "plan," "potential," "predict,"
"seek," "should," "would" or by variations of such words or by
similar expressions. The forward-looking statements include
statements relating to, among other things, REGENXBIO's future
operations and clinical trials. REGENXBIO has based these
forward-looking statements on its current expectations and
assumptions and analyses made by REGENXBIO in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors REGENXBIO believes are appropriate under the circumstances.
However, whether actual results and developments will conform with
REGENXBIO's expectations and predictions is subject to a number of
risks and uncertainties, including the timing of enrollment,
commencement and completion and the success of clinical trials
conducted by REGENXBIO, its licensees and its partners, the timing
of commencement and completion and the success of preclinical
studies conducted by REGENXBIO and its development partners, the
timely development and launch of new products, the ability to
obtain and maintain regulatory approval of product candidates, the
ability to obtain and maintain intellectual property protection for
product candidates and technology, trends and challenges in the
business and markets in which REGENXBIO operates, the size and
growth of potential markets for product candidates and the ability
to serve those markets, the rate and degree of acceptance of
product candidates, the impact of the COVID-19 pandemic or similar
public health crises on REGENXBIO's business, and other factors,
many of which are beyond the control of REGENXBIO. Refer to the
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of
REGENXBIO's Annual Report on Form 10-K for the year ended
December 31, 2022, and comparable
"risk factors" sections of REGENXBIO's Quarterly Reports on Form
10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at WWW.SEC.GOV. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. Except as required by law,
REGENXBIO does not undertake any obligation, and specifically
declines any obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-virtual-investor-day-highlighting-aav-pipeline-programs-with-upcoming-interim-trial-updates-301864128.html
SOURCE REGENXBIO Inc.